Key facts
- It has raised $2.1M; the latest was PE Growth/Expansion in Jun 2025.
- Notable investors include 1315 Capital, IOL Chemicals And Pharmaceuticals.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for USpharma (Pharmaceuticals)
- ·The full record, as it builds
Funding rounds
No funding rounds for USpharma (Pharmaceuticals) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About USpharma (Pharmaceuticals)
Manufacturer of pharmaceuticals focused on developing and commercialising brand and pharmaceutically equivalent products. The company develops transdermal, topical, tablets, capsules, modified release, soft chew and chewable bars for consumers and patients, thereby enabling access to products that improve health and wellness.
- Sector
- Healthcare
- HQ
- Miami Lakes, FL, United States
- Founded
- 2016
- Employees
- 78
- Website
- uspharmaltd.com/
- Ownership
- Privately Held (backing)
USpharma (Pharmaceuticals) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in USpharma (Pharmaceuticals) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on USpharma (Pharmaceuticals) in its N-PORT filings yet. We sweep new filings monthly.